COVID 19 update: Covid 19 associated coagulopathy
The Covid 19 pandemic has introduced an array of organspecific and systemic phenotypessome previously observed in viral infections, including severe acute respiratory syndrome (SARS) and others that appear to be unique to SARScoronavirus (CoV) 2. Rapidly emerging information from clinical observations, autopsy based findings, extrapolations from in vitro and ex vivo studies and dynamic modeling are informing management guidelines; however, many questions remain unanswered and clinical trials that are required to provide evidence have not been completed in most areas. Among the many questions that require careful thought, reflection and investigation are the mechanism(s) underlying the development of a systemic coagulopathy and acquired thrombophilia characterized in a majority of cases by a proclivity for venous, arterial and microvascular thrombosis. The following review summarizes emerging insights into the pathobiology, mechanism(s) diagnosis, management, foundations for research and either planned or ongoing clinical trials for Covid 19 associated coagulopathy.
Journal of Thrombosis and Thrombolysis